JPH11508605A - 自己免疫疾患および特にインスリン―依存性糖尿病の治療のためのil―7の使用 - Google Patents
自己免疫疾患および特にインスリン―依存性糖尿病の治療のためのil―7の使用Info
- Publication number
- JPH11508605A JPH11508605A JP9530667A JP53066797A JPH11508605A JP H11508605 A JPH11508605 A JP H11508605A JP 9530667 A JP9530667 A JP 9530667A JP 53066797 A JP53066797 A JP 53066797A JP H11508605 A JPH11508605 A JP H11508605A
- Authority
- JP
- Japan
- Prior art keywords
- autoimmune disease
- cells
- pharmaceutical composition
- autoimmune
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract description 54
- 108010002586 Interleukin-7 Proteins 0.000 title claims abstract description 16
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title claims description 25
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 30
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 28
- 102000000704 Interleukin-7 Human genes 0.000 claims abstract description 15
- 229940100994 interleukin-7 Drugs 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 38
- 108090000978 Interleukin-4 Proteins 0.000 claims description 24
- 230000017307 interleukin-4 production Effects 0.000 claims description 21
- 238000004519 manufacturing process Methods 0.000 claims description 21
- 230000007812 deficiency Effects 0.000 claims description 18
- 230000001363 autoimmune Effects 0.000 claims description 14
- 230000007547 defect Effects 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 14
- 102100032912 CD44 antigen Human genes 0.000 claims description 13
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 210000004241 Th2 cell Anatomy 0.000 claims description 11
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 6
- 230000005784 autoimmunity Effects 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 3
- 206010036030 Polyarthritis Diseases 0.000 claims description 3
- 208000034189 Sclerosis Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 201000002491 encephalomyelitis Diseases 0.000 claims description 3
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 206010062269 Adrenalitis Diseases 0.000 claims description 2
- 201000005000 autoimmune gastritis Diseases 0.000 claims description 2
- 208000027841 autoimmune hepatitis type 2 Diseases 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 description 42
- 206010012601 diabetes mellitus Diseases 0.000 description 29
- 102000004388 Interleukin-4 Human genes 0.000 description 21
- 229940028885 interleukin-4 Drugs 0.000 description 21
- 238000002474 experimental method Methods 0.000 description 11
- 238000002347 injection Methods 0.000 description 11
- 229940090044 injection Drugs 0.000 description 11
- 239000007924 injection Substances 0.000 description 11
- 238000000338 in vitro Methods 0.000 description 9
- 210000004989 spleen cell Anatomy 0.000 description 8
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 5
- 229960004397 cyclophosphamide Drugs 0.000 description 5
- 230000003832 immune regulation Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 238000012937 correction Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 210000001541 thymus gland Anatomy 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 101000663003 Homo sapiens Non-receptor tyrosine-protein kinase TNK1 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102100039064 Interleukin-3 Human genes 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 102100037669 Non-receptor tyrosine-protein kinase TNK1 Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012867 bioactive agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 229940108605 cyclophosphamide injection Drugs 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000007849 functional defect Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 108010066312 streptavidin-tricolor Proteins 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2046—IL-7
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.自己免疫疾患の治療のための薬剤または医薬組成物を調製するための、イ ンターロイキン−7または予めIL−7の存在下でインキュベートしたTリンパ 球の使用。 2.該自己免疫疾患がTh2細胞によるIL−4の産生における欠損により発 症されている、請求項1記載の使用。 3.該自己免疫疾患がサブタイプHSA-、CD4-CD8-またはCD4+CD 8-、CD44+、TCR−αβ+、Vβ8+、NK1.1+を有するT細胞の量的 および機能的欠如に関連したIL−4の産生における欠損により発症されている 、請求項1または請求項2記載の使用。 4.該自己免疫疾患がインスリン依存性糖尿病、自己免疫性脳脊髄炎、自己免 疫性慢性関節リウマチ、多発性関節炎、自己免疫性2型肝炎、自己免疫性胃炎、 自己免疫性硬化症、唾液腺炎、副腎炎、卵巣炎、糸球体腎炎、または自己免疫性 甲状腺炎またはAIDSの治療に結びつけられる治療における自己免疫型発症メ カニズムである、請求項1、2または3記載の使用。 5.該自己免疫疾患がインスリン依存性糖尿病である請求項1、2、3または 4記載の使用。 6.該Tリンパ球がそれらを含む医薬組成物が向けられる患者の細胞由来の自 己由来または同系細胞である、前記の請求項のいずれか1項記載の使用。 7.自己免疫疾患を治療するための医薬組成物であって、活性素因として、予 めIL−7の存在下でインキュベートされているその医薬組成物が向けられる患 者の細胞由来の自己由来または同系Tリンパ球を含む医薬組成物。 8.Th2細胞によるIL−4の産生における欠損により発症される自己免疫 疾患を治療するための請求項7記載の医薬組成物。 9.サブタイプHSA-、CD4-CD8-またはCD4+CD8-、CD44+、 TCR−αβ+、Vβ8+、NK1.1+の細胞の量的および機能的欠如に関連し たIL−4の産生における欠損により発症される自己免疫疾患を治療するための 、 請求項7または請求項8記載の医薬組成物。 10.インスリン依存性糖尿病を治療するための請求項7、8または9のいず れか1項記載の医薬組成物。 11.自己免疫疾患を治療するための医薬組成物の製法であって、予め医薬上 許容されるビヒクルまたは希釈剤とともにIL−7の存在下でインキュベートさ れている該組成物が向けられる患者の細胞由来の自己由来または同系Tリンパ球 を混合し、他の活性素因を結合させてもよいことからなる製法。 12.請求項11記載の自己免疫疾患を治療するための医薬組成物の製法であ って、該自己免疫疾患がTh2細胞によるIL−4の産生における欠損により発 症されている製法。 13.請求項11または請求項12記載の自己免疫疾患を治療するための医薬 組成物の製法であって、該自己免疫疾患がサブタイプHSA-、CD4-CD8- またはCD4+CD8-、CD44+、TCR−αβ+、Vβ8+、NK1.1+を有 するT細胞の量的および機能的欠如に関連したIL−4の産生における欠損によ り発症されている製法。 14.請求項11、12または13記載の自己免疫疾患を治療するための医薬 組成物の製法であって、該自己免疫疾患がインスリン依存性糖尿病である製法。 15.治療上有効投薬量のインターロイキン−7または予めIL−7の存在下 でインキュベートされたTリンパ球を自己免疫疾患を有する患者に投与する、治 療的処置方法。 16.治療上有効投薬量のインターロイキン−7または予めIL−7の存在下 でインキュベートされたTリンパ球をインスリン依存性糖尿病を有する患者に投 与する、治療的処置方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9602501A FR2745185B1 (fr) | 1996-02-28 | 1996-02-28 | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant |
FR96/02501 | 1996-02-28 | ||
PCT/FR1997/000343 WO1997031648A1 (fr) | 1996-02-28 | 1997-02-26 | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11508605A true JPH11508605A (ja) | 1999-07-27 |
JP3138481B2 JP3138481B2 (ja) | 2001-02-26 |
Family
ID=9489676
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP09530667A Expired - Lifetime JP3138481B2 (ja) | 1996-02-28 | 1997-02-26 | 自己免疫疾患および特にインスリン―依存性糖尿病の治療のためのil―7の使用 |
Country Status (13)
Country | Link |
---|---|
US (2) | US6713053B1 (ja) |
EP (1) | EP0883406B1 (ja) |
JP (1) | JP3138481B2 (ja) |
AT (1) | ATE264112T1 (ja) |
AU (1) | AU1929397A (ja) |
BR (1) | BR9707776A (ja) |
DE (1) | DE69728654T2 (ja) |
DK (1) | DK0883406T3 (ja) |
ES (1) | ES2217396T3 (ja) |
FR (1) | FR2745185B1 (ja) |
NO (1) | NO321569B1 (ja) |
PT (1) | PT883406E (ja) |
WO (1) | WO1997031648A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016530298A (ja) * | 2013-09-05 | 2016-09-29 | サンフォード−バーンハム メディカル リサーチ インスティテュート | γδT細胞の調節 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2745185B1 (fr) * | 1996-02-28 | 1998-05-15 | Sanofi Sa | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant |
SA114360064B1 (ar) * | 2010-02-24 | 2016-01-05 | رينات نيوروساينس كوربوريشن | طرق وأجسام مضادة معارضة ضد مستقبل il-7 |
GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
JP6081483B2 (ja) | 2011-12-12 | 2017-02-15 | セル・メディカ・リミテッド | T細胞を増殖させるプロセス |
DK3591047T3 (da) | 2012-02-09 | 2022-10-24 | Baylor College Medicine | Peptidblandinger til generering af multivirale CTL¿er med bred specificitet |
JP6999941B2 (ja) | 2015-09-18 | 2022-02-10 | ベイラー カレッジ オブ メディスン | 病原体からの免疫原性抗原同定および臨床的有効性との相関 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5032396A (en) * | 1989-02-17 | 1991-07-16 | Immunex Corporation | IL-7 to stimulate platelet production |
US5229115A (en) * | 1990-07-26 | 1993-07-20 | Immunex Corporation | Adoptive immunotherapy with interleukin-7 |
US5474769A (en) * | 1991-03-08 | 1995-12-12 | Sterling Winthrop Inc. | Treatment of microbial infection by monocyte stimulation with interleukin-7 |
US6576236B1 (en) * | 1994-07-01 | 2003-06-10 | Dana Farber Cancer Institute | Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain |
FR2745185B1 (fr) * | 1996-02-28 | 1998-05-15 | Sanofi Sa | Utilisation de l'il-7 dans le traitement des maladies auto-immunes, en particulier le diabete mellitus insulinodependant |
-
1996
- 1996-02-28 FR FR9602501A patent/FR2745185B1/fr not_active Expired - Lifetime
-
1997
- 1997-02-26 AU AU19293/97A patent/AU1929397A/en not_active Abandoned
- 1997-02-26 DK DK97907134T patent/DK0883406T3/da active
- 1997-02-26 PT PT97907134T patent/PT883406E/pt unknown
- 1997-02-26 DE DE69728654T patent/DE69728654T2/de not_active Expired - Lifetime
- 1997-02-26 JP JP09530667A patent/JP3138481B2/ja not_active Expired - Lifetime
- 1997-02-26 WO PCT/FR1997/000343 patent/WO1997031648A1/fr active IP Right Grant
- 1997-02-26 BR BR9707776A patent/BR9707776A/pt not_active Application Discontinuation
- 1997-02-26 AT AT97907134T patent/ATE264112T1/de active
- 1997-02-26 ES ES97907134T patent/ES2217396T3/es not_active Expired - Lifetime
- 1997-02-26 EP EP97907134A patent/EP0883406B1/fr not_active Expired - Lifetime
- 1997-02-26 US US09/125,168 patent/US6713053B1/en not_active Expired - Lifetime
-
1998
- 1998-08-26 NO NO19983917A patent/NO321569B1/no not_active IP Right Cessation
-
2004
- 2004-03-26 US US10/810,109 patent/US20040180037A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016530298A (ja) * | 2013-09-05 | 2016-09-29 | サンフォード−バーンハム メディカル リサーチ インスティテュート | γδT細胞の調節 |
US10759863B2 (en) | 2013-09-05 | 2020-09-01 | Sanford Burnham Prebys Medical Discovery Institute | Modulation of γδ T cells |
Also Published As
Publication number | Publication date |
---|---|
WO1997031648A1 (fr) | 1997-09-04 |
NO983917D0 (no) | 1998-08-26 |
NO983917L (no) | 1998-10-28 |
DK0883406T3 (da) | 2004-08-02 |
BR9707776A (pt) | 1999-07-27 |
US20040180037A1 (en) | 2004-09-16 |
DE69728654T2 (de) | 2005-03-24 |
FR2745185B1 (fr) | 1998-05-15 |
DE69728654D1 (de) | 2004-05-19 |
US6713053B1 (en) | 2004-03-30 |
AU1929397A (en) | 1997-09-16 |
PT883406E (pt) | 2004-08-31 |
FR2745185A1 (fr) | 1997-08-29 |
JP3138481B2 (ja) | 2001-02-26 |
ATE264112T1 (de) | 2004-04-15 |
EP0883406B1 (fr) | 2004-04-14 |
EP0883406A1 (fr) | 1998-12-16 |
ES2217396T3 (es) | 2004-11-01 |
NO321569B1 (no) | 2006-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Clayberger et al. | Immunoregulatory activities of autoreactive T cells: an IA-specific T cell clone mediates both help and suppression of antibody responses. | |
RU2120802C1 (ru) | Фармацевтическая композиция, предназначенная для торможения зависимой от интерлейкина-2 пролиферации опухолевых клеток, увеличения содержания интерферона, лечения воспалительных заболеваний кишечника, потенцирования торможения производства цитокина и ограничения или торможения аллергической реакции замедленного типа | |
US5096704A (en) | Method of treating eosinophilia | |
JPH07508711A (ja) | Cd28経路免疫調節 | |
US5296353A (en) | Evaluation and treatment of patients with progessive immunosuppression | |
Lamhamedi-Cherradi et al. | Resistance of T-cells to apoptosis in autoimmune diabetic (NOD) mice is increased early in life and is associated with dysregulated expression of Bcl-x | |
Steptoe et al. | Autoimmune diabetes is suppressed by transfer of proinsulin-encoding Gr-1+ myeloid progenitor cells that differentiate in vivo into resting dendritic cells | |
DE69333760T2 (de) | Evaluierung von patienten mit progressiver immunosuppression | |
KR100275656B1 (ko) | 다형성의 클래스 ii mhc 동종펩타이드를 이용한 림프구 증식의 억제 및 면역관용의 유도 방법 | |
JP2000509604A (ja) | サプレッサー細胞集団を生成するためのインターロイキン―10の使用 | |
DE69535713T2 (de) | Verfahren zur modulierung von t-zellreaktionen durch manipulation einer gemeinsamen zytokinrezeptor-gammakette | |
JP2002531123A (ja) | ヒトの乾癬を予防及び治療するための乾癬モデル動物 | |
Parkinson et al. | Altered natural killer cell biology in C57BL/6 mice after leukemogenic split-dose irradiation. | |
Pankewycz et al. | A protective NOD islet‐infiltrating CD8+ T cell clone, IS 2.15, has in vitro immunosuppressive properties | |
JPH11508605A (ja) | 自己免疫疾患および特にインスリン―依存性糖尿病の治療のためのil―7の使用 | |
Mariotti et al. | The autoimmune infiltrate of Basedow's disease: analysis at clonal level and comparison with Hashimoto's thyroiditis | |
JP2012508575A (ja) | Foxp3+ナチュラルキラーT細胞および免疫関連疾患の治療方法 | |
Taga et al. | Preferential expression of IL-2 receptor subunits on memory populations within CD4+ and CD8+ T cells. | |
CA2134083C (en) | Prophylactic and therapeutic agents for autoimmune diseases | |
DE60130634T2 (de) | Identifizierung von antigenen peptiden durch zytotoxische t-lymphozyten aktiviert von dendritischen zellhybriden | |
Govallo | Immunology of pregnancy and cancer | |
Ito et al. | Regulation of autoimmune diabetes by interleukin 3-dependent bone marrow-derived cells in NOD mice | |
JP2000515007A (ja) | T細胞選択的インターロイキン―4アゴニスト | |
Sun et al. | Human prolactin improves engraftment and reconstitution of human peripheral blood lymphocytes in SCID mice | |
JPH11510806A (ja) | 免疫抑制治療のためのインターロイキン10およびシクロスポリンの併用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R370 | Written measure of declining of transfer procedure |
Free format text: JAPANESE INTERMEDIATE CODE: R370 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071208 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081208 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091208 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101208 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101208 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111208 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111208 Year of fee payment: 11 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121208 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121208 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131208 Year of fee payment: 13 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |